J
James J. Goedert
Researcher at National Institutes of Health
Publications - 476
Citations - 50964
James J. Goedert is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 103, co-authored 469 publications receiving 47899 citations. Previous affiliations of James J. Goedert include Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
Michael Dean,Mary Carrington,Cheryl A. Winkler,Gavin A. Huttley,Michael W. Smith,Rando Allikmets,James J. Goedert,Susan Buchbinder,Eric Vittinghoff,Edward D. Gomperts,Sharyne Donfield,David Vlahov,Richard A. Kaslow,Alfred J. Saah,Charles R. Rinaldo,Roger Detels,Stephen J. O'Brien +16 more
TL;DR: The CKR5Δ32 deletion may act as a recessive restriction gene against HIV-1 infection and may exert a dominant phenotype of delaying progression to AIDS among infected individuals.
Journal ArticleDOI
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
David L. Thomas,Chloe L. Thio,Maureen P. Martin,Ying Qi,Dongliang Ge,Colm O'hUigin,Judith R. Kidd,Kenneth K. Kidd,Salim I. Khakoo,Graeme J.M. Alexander,James J. Goedert,Gregory D. Kirk,Sharyne M. Donfield,Hugo R. Rosen,Leslie H. Tobler,Michael P. Busch,John G. McHutchison,David Goldstein,Mary Carrington +18 more
TL;DR: It is shown that the C/C genotype strongly enhances resolution of HCV infection among individuals of both European and African ancestry, the strongest and most significant genetic effect associated with natural clearance ofHCV.
Journal ArticleDOI
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
Mary Carrington,George W. Nelson,Maureen P. Martin,Teri Kissner,David Vlahov,James J. Goedert,Richard A. Kaslow,Susan Buchbinder,Keith Hoots,Stephen J. O'Brien +9 more
TL;DR: The extended survival of 28 to 40 percent of HIV-1-infected Caucasian patients who avoided AIDS for ten or more years can be attributed to their being fully heterozygous at HLA class I loci, to their lacking the AIDS-associated alleles B*35 and Cw*04, or to both.
Journal ArticleDOI
Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada.
Hasina Samji,Angela Cescon,Robert S. Hogg,Robert S. Hogg,Sharada P. Modur,Keri N. Althoff,Kate Buchacz,Ann N. Burchell,Mardge H. Cohen,Kelly A. Gebo,M. John Gill,Amy C. Justice,Gregory D. Kirk,Marina B. Klein,P. Todd Korthuis,Jeffrey N. Martin,Sonia Napravnik,Sean B. Rourke,Timothy R. Sterling,Michael J. Silverberg,Stephen G. Deeks,Lisa P. Jacobson,Ronald J. Bosch,Mari M. Kitahata,James J. Goedert,Richard D. Moore,Stephen J. Gange +26 more
TL;DR: A 20-year-old HIV-positive adult on ART in the U.S. or Canada is expected to live into their early 70 s, a life expectancy approaching that of the general population.
Journal ArticleDOI
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS
Maureen P. Martin,Xiaojiang Gao,Jeong Hee Lee,George W. Nelson,Roger Detels,James J. Goedert,Susan Buchbinder,Keith Hoots,David Vlahov,John Trowsdale,Michael A Wilson,Michael A Wilson,Stephen J. O'Brien,Mary Carrington +13 more
TL;DR: The strongest synergistic effect of these loci was on progression to depletion of CD4+ T cells, which suggests that a protective response of NK cells involving KIR3DS1 and its HLA class I ligands begins soon after HIV-1 infection.